Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress, Psychological | 14 | 2020 | 345 | 3.010 |
Why?
|
| Affect | 14 | 2017 | 397 | 2.280 |
Why?
|
| Alcohol Drinking | 7 | 2021 | 287 | 2.130 |
Why?
|
| Ethanol | 6 | 2021 | 270 | 1.850 |
Why?
|
| Central Nervous System Stimulants | 9 | 2018 | 235 | 1.710 |
Why?
|
| Behavior, Addictive | 2 | 2024 | 137 | 1.330 |
Why?
|
| Caffeine | 6 | 2014 | 86 | 1.330 |
Why?
|
| Dextroamphetamine | 6 | 2016 | 108 | 1.240 |
Why?
|
| Emotions | 5 | 2018 | 377 | 1.190 |
Why?
|
| Central Nervous System Depressants | 3 | 2017 | 45 | 0.950 |
Why?
|
| Reward | 3 | 2018 | 209 | 0.860 |
Why?
|
| Young Adult | 23 | 2018 | 7025 | 0.810 |
Why?
|
| Heart Rate | 9 | 2020 | 519 | 0.710 |
Why?
|
| Hydrocortisone | 11 | 2016 | 300 | 0.690 |
Why?
|
| Double-Blind Method | 13 | 2018 | 1791 | 0.690 |
Why?
|
| Substance-Related Disorders | 3 | 2024 | 451 | 0.690 |
Why?
|
| Choice Behavior | 3 | 2013 | 165 | 0.680 |
Why?
|
| Amygdala | 2 | 2018 | 87 | 0.680 |
Why?
|
| Laboratories | 1 | 2020 | 48 | 0.630 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 68 | 0.620 |
Why?
|
| Hormones | 2 | 2010 | 144 | 0.580 |
Why?
|
| Binge Drinking | 1 | 2018 | 15 | 0.570 |
Why?
|
| Sensation | 1 | 2018 | 52 | 0.560 |
Why?
|
| Adult | 28 | 2018 | 28716 | 0.560 |
Why?
|
| Smoking | 4 | 2010 | 653 | 0.550 |
Why?
|
| Corpus Striatum | 1 | 2018 | 92 | 0.550 |
Why?
|
| Blood Pressure | 6 | 2017 | 929 | 0.530 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2017 | 12 | 0.530 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 150 | 0.510 |
Why?
|
| Dronabinol | 1 | 2017 | 59 | 0.490 |
Why?
|
| Virtual Reality | 1 | 2017 | 39 | 0.490 |
Why?
|
| Alcohol-Related Disorders | 2 | 2017 | 18 | 0.490 |
Why?
|
| Dietary Supplements | 2 | 2014 | 133 | 0.480 |
Why?
|
| Male | 29 | 2020 | 45870 | 0.480 |
Why?
|
| Space Perception | 1 | 2017 | 120 | 0.470 |
Why?
|
| Psychomotor Performance | 4 | 2017 | 505 | 0.450 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 290 | 0.450 |
Why?
|
| Energy Drinks | 1 | 2014 | 2 | 0.450 |
Why?
|
| Adolescent | 15 | 2017 | 9896 | 0.420 |
Why?
|
| Female | 26 | 2020 | 50030 | 0.410 |
Why?
|
| Conditioning, Classical | 3 | 2021 | 38 | 0.390 |
Why?
|
| Personality | 1 | 2014 | 140 | 0.390 |
Why?
|
| Humans | 34 | 2024 | 96093 | 0.380 |
Why?
|
| Progesterone | 2 | 2010 | 112 | 0.380 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2010 | 16 | 0.360 |
Why?
|
| Quinoxalines | 1 | 2012 | 51 | 0.360 |
Why?
|
| Cognition | 2 | 2014 | 635 | 0.360 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.360 |
Why?
|
| Eye Movements | 1 | 2012 | 119 | 0.350 |
Why?
|
| Nicotinic Agonists | 1 | 2012 | 74 | 0.350 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 423 | 0.340 |
Why?
|
| Motivation | 2 | 2016 | 310 | 0.340 |
Why?
|
| Sleep | 1 | 2014 | 458 | 0.330 |
Why?
|
| Attention | 1 | 2014 | 413 | 0.320 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 36 | 0.320 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 59 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 1973 | 0.290 |
Why?
|
| Brain | 2 | 2017 | 2482 | 0.290 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2008 | 57 | 0.270 |
Why?
|
| Tobacco Use Disorder | 1 | 2008 | 122 | 0.270 |
Why?
|
| Placebos | 4 | 2011 | 213 | 0.260 |
Why?
|
| Anxiety | 5 | 2010 | 339 | 0.260 |
Why?
|
| Healthy Volunteers | 2 | 2018 | 157 | 0.260 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 156 | 0.260 |
Why?
|
| Fatigue | 1 | 2008 | 185 | 0.260 |
Why?
|
| Neural Pathways | 2 | 2018 | 333 | 0.240 |
Why?
|
| Social Environment | 2 | 2006 | 195 | 0.240 |
Why?
|
| Behavior | 1 | 2006 | 87 | 0.230 |
Why?
|
| Psychological Tests | 2 | 2017 | 91 | 0.230 |
Why?
|
| Breath Tests | 2 | 2018 | 58 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 2860 | 0.230 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 829 | 0.210 |
Why?
|
| Analysis of Variance | 3 | 2017 | 910 | 0.210 |
Why?
|
| Area Under Curve | 2 | 2016 | 340 | 0.200 |
Why?
|
| Saliva | 4 | 2014 | 128 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 3651 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 2473 | 0.160 |
Why?
|
| Norepinephrine | 2 | 2010 | 174 | 0.150 |
Why?
|
| Environment | 2 | 2011 | 231 | 0.140 |
Why?
|
| Euphoria | 2 | 2017 | 47 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2018 | 162 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2017 | 688 | 0.140 |
Why?
|
| Functional Neuroimaging | 1 | 2017 | 32 | 0.130 |
Why?
|
| Sex Characteristics | 2 | 2010 | 339 | 0.130 |
Why?
|
| Gyrus Cinguli | 1 | 2017 | 49 | 0.130 |
Why?
|
| Pleasure | 1 | 2017 | 14 | 0.130 |
Why?
|
| Extinction, Psychological | 1 | 2017 | 21 | 0.130 |
Why?
|
| Spatial Behavior | 1 | 2017 | 20 | 0.130 |
Why?
|
| Heart | 1 | 2020 | 592 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 1 | 2017 | 118 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 66 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2012 | 504 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1874 | 0.110 |
Why?
|
| Performance-Enhancing Substances | 1 | 2014 | 1 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 328 | 0.110 |
Why?
|
| Personality Tests | 1 | 2014 | 21 | 0.110 |
Why?
|
| Memory | 1 | 2017 | 229 | 0.110 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 35 | 0.110 |
Why?
|
| Buprenorphine | 1 | 2014 | 51 | 0.110 |
Why?
|
| Time Factors | 4 | 2012 | 5585 | 0.100 |
Why?
|
| Nerve Net | 1 | 2017 | 407 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 615 | 0.100 |
Why?
|
| Theobromine | 1 | 2013 | 3 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 438 | 0.100 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2010 | 132 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2012 | 24 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 513 | 0.090 |
Why?
|
| Varenicline | 1 | 2012 | 16 | 0.090 |
Why?
|
| Central Nervous System Sensitization | 1 | 2011 | 10 | 0.090 |
Why?
|
| Association Learning | 1 | 2011 | 38 | 0.090 |
Why?
|
| Infusion Pumps | 1 | 2011 | 27 | 0.090 |
Why?
|
| Acute Disease | 2 | 2012 | 872 | 0.090 |
Why?
|
| Methamphetamine | 1 | 2013 | 104 | 0.090 |
Why?
|
| Cues | 1 | 2013 | 189 | 0.090 |
Why?
|
| Discrimination Learning | 1 | 2011 | 65 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 199 | 0.080 |
Why?
|
| Outpatients | 1 | 2011 | 105 | 0.080 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2010 | 8 | 0.080 |
Why?
|
| Nausea | 1 | 2012 | 182 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2883 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 97 | 0.080 |
Why?
|
| Luteal Phase | 1 | 2010 | 14 | 0.080 |
Why?
|
| Students | 1 | 2011 | 179 | 0.080 |
Why?
|
| Pituitary-Adrenal System | 1 | 2009 | 64 | 0.080 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2009 | 81 | 0.080 |
Why?
|
| Dopamine | 2 | 2008 | 282 | 0.080 |
Why?
|
| Pregnanolone | 1 | 2008 | 8 | 0.070 |
Why?
|
| Naltrexone | 1 | 2009 | 139 | 0.070 |
Why?
|
| Capsules | 1 | 2008 | 38 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 30 | 0.070 |
Why?
|
| Speech | 1 | 2008 | 91 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2017 | 4671 | 0.070 |
Why?
|
| Logistic Models | 1 | 2011 | 1268 | 0.070 |
Why?
|
| Self-Assessment | 1 | 2008 | 48 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2008 | 120 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2011 | 815 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 174 | 0.070 |
Why?
|
| Research Design | 1 | 2011 | 631 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 547 | 0.060 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 44 | 0.060 |
Why?
|
| Arousal | 1 | 2006 | 173 | 0.060 |
Why?
|
| Adenosine | 1 | 2008 | 278 | 0.060 |
Why?
|
| Reaction Time | 1 | 2006 | 323 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1958 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2008 | 565 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 1882 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2006 | 244 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2494 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1932 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2008 | 1423 | 0.040 |
Why?
|
| Middle Aged | 2 | 2017 | 28361 | 0.040 |
Why?
|
| Animals | 2 | 2011 | 28914 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1807 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 131 | 0.020 |
Why?
|
| Barbiturates | 1 | 2011 | 12 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 133 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 10 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 2010 | 13 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 285 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2013 | 514 | 0.020 |
Why?
|
| Hallucinogens | 1 | 2011 | 84 | 0.020 |
Why?
|
| Anger | 1 | 2010 | 81 | 0.020 |
Why?
|
| Individuality | 1 | 2010 | 114 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2009 | 170 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 338 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 639 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2010 | 781 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 2579 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 1564 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 2480 | 0.010 |
Why?
|